PARP (poly ADP-ribose polymerase) inhibition is a type of targeted cancer therapy that specifically targets cancer cells with defects in DNA repair mechanisms. PARP enzymes help repair damaged DNA, and inhibiting them can prevent cancer cells from repairing DNA damage, leading to their death. PARP inhibitors have shown promising results in the treatment of various types of cancer, particularly those with mutations in BRCA genes, which are involved in DNA repair. This research area is focused on developing and improving PARP inhibitors as a novel therapeutic approach for cancer treatment.